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Antibiotic resistance is an ever-growing problem yet the development of new antibiotics has slowed to a trickle, giving rise to
the use of combination therapy to eradicate infections. The purpose of this study was to evaluate the combined inhibitory
eﬀect of lithium ﬂuoride (LiF) and commonly used antimicrobials on the growth of the following bacteria: Enterococcus
faecalis, Staphyloccoccus aureus, Escherichia coli, Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Serratia
marcescens,a n dStreptococcus pneumoniae.T h ein vitro activities of ceftazidime, sulfamethoxazole-trimethoprim, streptomycin,
erythromycin, amoxicillin, and ciproﬂoxacin, doxycycline, alone or combined with LiF were performed by microdilution method.
MICs were determined visually following 18–20h of incubation at 37◦C. We observed reduced MICs of antibiotics associated with
LiF ranging from two-fold to sixteen-fold. The strongest decreases of MICs observed were for streptomycin and erythromycin
associated with LiF against Acinetobacter baumannii and Streptococcus pneumoniae. An eight-fold reduction was recorded for
streptomycin against S. pneumoniae whereas an eight-fold and a sixteen-fold reduction were obtained for erythromycin against A.
baumannii and S. pneumoniae. This suggests that LiF exhibits a synergistic eﬀect with a wide range of antibiotics and is indicative
of its potential as an adjuvant in antibiotic therapy.
1.Introduction
The advent of penicillin, an antibiotic produced by the
fungus Penicillium, marked a historic event in the medical
ﬁeld. Alexander Fleming ﬁrst observed the antibiotic activity
of penicillin against Staphylococcus aureus in Petri dishes.
The discovery of penicillin, labeled the miracle drug, led
physicians to believe the war with bacteria was over until the
appearance of resistant strains. This led to the development
ofmethicillintocombatinfectionscausedbyS.aureusstrains
resistant to penicillin. The cycle of creating new antibiotics
and bacteria becoming resistant to them has contributed to
the antibiotic resistance pandemic we are currently facing
[1,2].Theincreaseinantibioticresistancecoincidedwiththe
declineintheproductionofnewantibiotics[3].Accordingly,
the use of combination therapy has evolved as an alternative
to treat resistant pathogens. Combination therapy consists of
using either two antibiotics or an antibiotic and an adjuvant
to circumvent infections caused by pathogens resistant to
antibiotics. Antibiotics used in combination therapy should
act independently of each other. Successful combination
therapy is characterized by a synergistic eﬀect of the
antibiotics or the antibiotic and the adjuvant demonstrated
by a reduction in either the (MIC) minimal inhibitory
concentration or (MBC) bactericidal concentration minimal
of the antibiotic. In addition to reducing the dose of the
antibiotic, combination therapy decreases the side eﬀects of
antibiotic therapy while slowing the emergence of resistance
[3, 4].
The use of ﬂuoride either alone or in combination ther-
apy to combat caries has proved to be an eﬀective practice
in reducing the growth of cariogenic Streptococci.F l u o r i d e
inhibits enolase, a glycolytic enzyme coded by an essential
gene and highly conserved among diﬀerent forms of life2 International Journal of Microbiology
ranging from archaebacteria and eubacteria to parasites and
mammals [5, 6]. Enolase is a moonlighting protein which
has been demonstrated to play roles in adhesion and in
gene regulation [7, 8]. When used in combination therapy,
ﬂuoride is most commonly associated with cations which
increase its antimicrobial properties. Diﬀerent cations act as
adjuvants to augment the antimicrobial activities of ﬂuoride
at varying degrees [9]. For example, AmF (amine ﬂuoride)
has been reported to be a stronger antimicrobial agent
than NaF in the goal of eliminating caries-causing bacteria.
The reason for this increased antimicrobial activity is not
known but is thought to be related to a stronger inhibition
of acid production by AmF [9, 10]. Furthermore, lithium
exerts an adjuvant potential towards ﬂuoride by increasing
the antimicrobial properties of ﬂuoride through poorly
understood mechanisms [11]. Lithium has been employed
as an adjuvant in oral vaccines against hepatitis B and acts
by increasing the properties of aluminum in these vaccines
[12].
The goal of this study was to determine the eﬀects of
LiF on antibiotics used against the planktonic form of the
bacteria commonly associated with nosocomial infections:
Enterococcus faecalis, S. aureus, Escherichia coli, Pseudomonas
aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae,
Serratia marcescens, and Streptococcus pneumoniae [2]. The
antibiotics used in this study vary in the range of their
target site and mode of action. We used members of the
penicillin, beta-lactam, tetracycline, quinolone, macrolide,
aminoglycoside, and sulfamide and trimethoprim families.
Precisely, amoxicillin and ceftazidime were the penicillin
and beta-lactam used, respectively, both of which inhibit
peptidoglycan synthesis. Doxycycline was the tetracycline in
our study while streptomycin and erythromycin were the
aminoglycoside and macrolide, respectively; all three are
protein synthesis inhibitors. Our quinolone, ciproﬂoxacin,
interferes with DNA synthesis. Sulfamethoxazole, our sul-
famide, was used with trimethoprim, to impede synthesis of
folicacid[13].WeobtainedreductionsinMICsofantibiotics
associated with LiF ranging from twofold to sixteenfold.
The reductions in the MICs of all the antibiotics tested are
indicative of the potential LiF has as an adjuvant in antibi-
otic therapy. Our sharpest reductions observed were with
streptomycin and erythromycin against S. pneumoniae.T h e
more pronounced reduction in the MICs of streptomycin
and erythromycin associated with LiF against S. pneumoniae
was the result of this organism being more susceptible to
ﬂuoride than the other bacteria used in this study.
2.MaterialsandMethods
2.1. Antimicrobial Agents. Standard antibiotic powders were
purchased from Sigma-Aldrich Ltd (Montr´ eal, Qc, Canada):
ceftazidime, sulfamethoxazole-trimethoprim, streptomycin,
erythromycin, amoxicillin, ciproﬂoxacin, and doxycycline.
All of these compounds were diluted and stored according to
the manufacturer’s recommendations at −70◦C until used.
2.2. Chemicals. Concentrated LiF (32mg/L) stock solutions
were prepared in double-deionized water, ﬁlter-sterilized,
and stored in propylene containers. Stock solutions were
diluted prior to use and were added to wells at a ﬁnal
concentration of 8mg/L.
2.3. Test Organisms. The test organisms included eight
American Type Culture Collection, (Rockville, MD, USA)
ATCC strains which have been proposed as either quality
control strains or reference strains: ATCC 29212 Enterococ-
cus faecalis, ATCC29213 Staphylococcus aureus, ATCC49619
Streptococcus pneumoniae, ATCC 25922 Escherichia coli,a n d
ATCC 27653 Pseudomonas aeruginosa, ATCC 19606 Acineto-
bacterbaumannii, ATCC 13883 Klebsiella pneumoniae,A T C C
43861 Serratia marcescens.
2.4. Antibiotic Susceptibility Testing. Antibiotic susceptibility
of our bacterial strains was tested by broth microdilution
according to the guidelines from the Clinical and Laboratory
Standards Institute [14]. Brieﬂy, bacterial strains were grown
in cation-adjusted Mueller-Hinton broth for 18–20 hours
at 37◦C. A bacterial suspension was prepared and adjusted
to 0.5 McFarland turbidity standard (approximately 1 to
2 × 108 CFU/mL). A 1:100 dilution followed by a 1:2
dilution was performed to yield a starting inoculum of 5
× 105 CFU/mL. One hundred microliters of the bacterial
suspension was added to each well of microdilution tray
containing 50µL of LiF combined with 50µL of one of the
above antimicrobials at a concentration equal to two times
the ﬁnal concentration. The trays were incubated at 37◦C.
MICs were recorded following 18–20 hours of incubation.
The MIC resulted in complete visual inhibition of growth.
Susceptibilitytestswererepeatedonthreeseparateoccasions.
Wells containing 200µL of fresh medium served as the
negative control. The positive control consisted of wells
inoculated with 100 microliters of the tested bacterial strain
and 100µLo fm e d i u m .
3. Results
The eﬀect of LiF associated with antibiotics against eight
ATCC strains of Gram-positive and Gram-negative bacteria
is shown in Tables 1 and 2.
We observed reductions in MICs of antibiotics ranging
fromeightfoldtotwofoldagainsttheorganismstestedabove.
An eightfold reduction in the MIC of DOX (doxycycline)
against S. aureus and fourfold reductions of the MICs of CFT
(ceftazidime) and TMX (sulfamethoxazole-trimethoprim)
againstE.coliwereobtained.TwofoldreductionsintheMICs
of DOX and TMX against E. faecalis were recorded as were
twofold reductions in the MICs of CFT and TMX against S.
aureus and P. aeruginosa. A twofold reduction in the MIC of
DOXassociatedtoLiFagainstE.coliwasalsonoted(Table 1).
A sixteenfold reduction in the MIC of ERT (ery-
thromycin) was obtained against S. pneumoniae. Eightfold
reductions in the MICs of ERT against A. baumannii and
of STP (streptomycin) against S. pneumoniae were observed.
Fourfold reductions in the MICs of ERT and AMX (amoxi-
cillin) against K. pneumoniae and in the MICs of AMX and
CPF (ciproﬂoxacin) against S. marcescens and S. pneumoniaeInternational Journal of Microbiology 3
Table 1: MICs (µg/mL) of doxycycline, ceftazidime, and sulfamethoxazole-trimethoprim alone or in combination with LiF on Enterococcus
faecalis, Staphylococcus aureus, Escherichia coli,a n dPseudomonas aeruginosa.
Antimicrobial agents
MIC (µg/mL) DOX DOX + LiF CFT CFT + LiF TMX TMX + LiF
Bacterial strain
E. faecalis ATCC 29212 8.0 4.0 NT NT 0.125 0.06
S. aureus ATCC 29213 0.125 0.03 2.0 1.0 0.50 0.25
E. coli ATCC 25922 1.0 0.5 0.25 0.06 0.25 0.06
P. aeruginosa ATCC 27653 NT NT 2.0 1.0 16.0 8.0
DOX: doxycycline, CFT: ceftazidime, TMX: sulfamethoxazole-trimethoprim, NT: not tested.
Table 2: MICs (µg/mL) of streptomycin, erythromycin, amoxicillin, and ciproﬂoxacin alone or in combination with LiF on planktonic
Acinetobacter baumannii, Klebsiella pneumoniae, Serratia marcescens,a n dStreptococcus pneumoniae.
Antimicrobial agents
MIC (µg/mL) STP STP + LiF ERT ERT + LiF AMX AMX + LiF CPF CPF + LiF
Bacterial strain
A. baumannii 128 64 128 16 >128 64 1 0.5
ATCC 19606
K. pneumoniae 1.0 0.5 64 16 16 4 0.125 0.0625
ATCC 13883
S. marcescens 16 8 16 8 8 2 0.25 0.0625
ATCC 43861
S. pneumoniae 0.25 0.03 0.25 0.015 0.06 0.015 0.06 0.015
ATCC 49619
STP: streptomycin, ERT: erythromycin, AMX: amoxicillin, CPF: ciproﬂoxacin.
were noted. A greater-than-two-fold reduction in the MIC
of AMX was observed against A. baumannii.T w o f o l d
reductions in the MICs of STP and CPF were observed
against A. baumannii and K. pneumoniae as were twofold
reductions in the MICs of STP and ERT against S. marcescens
(Table 2).
4. Discussion
The goal of this study was to determine the adjuvant poten-
tial of LiF when associated with antibiotics commonly used
in the clinical setting against bacteria frequently linked to
nosocomial infections. The use of ﬂuoride as an antimi-
crobial agent derives from the ﬁeld of dentistry where it
was ﬁrst observed that ﬂuoride arrested the growth of
cariogenic streptococci by inhibiting the glycolytic enzyme
enolase [6]. A study by Maehara et al. [15] demonstrated
that ﬂuoride and xylitol act synergistically to suppress sugar
metabolisminMutansstreptococcileadingtoreducedgrowth
of these organisms. We are pleased to report reductions in
the MICs of all the antibiotics associated with LiF tested
in our study. The association of LiF with doxycycline,
ceftazidime, and sulfamethoxazole-trimethroprim against E.
faecalis, S. aureus, E. coli,a n dP. aeruginosa was evaluated
(Table 1). We also investigated the association with LiF to
streptomycin, erythromycin, amoxicillin, and ciproﬂoxacin
against A. baumannii, K. pneumoniae, S. marcescens,a n dS.
pneumoniae (Table 2). We observed a twofold reduction in
the MIC of doxycycline associated with LiF against E. faecalis
and E. coli and a fourfold reduction against S. aureus.T h e
greater decrease in the MIC of doxycycline suggests that
this association is more eﬀective in S. aureus than in E. coli
and E. faecalis. We expected to see a greater reduction in
the MIC against E. coli as enolase is a component of the
mRNA degradosome in this organism and has been shown
to bind the RNAse E within the degradosome [5]. Indeed,
interactions between enolase and putative RNAses involved
in mRNA degradation in Bacillus subtilis and Streptococci
pyogenes have been reported suggesting a role in gene
regulation for enolase [8, 16]. Although no interaction has
beenreportedbetweentheputativeRNaseinvolvedinmRNA
degradation and enolase in S. aureus [17], we nonetheless
believe that an inhibition of enolase by LiF would interfere
with gene regulation mechanisms in S. aureus. This is
because a stronger reduction in the MIC of doxycycline
associated with LiF against S. aureus was observed than
those against E. faecalis and E. coli. Moreover, the twofold
reductionsintheMICsofceftazidimeandsulfamethoxazole-
trimethoprim associated with LiF, neither of which targets
protein synthesis and hence does not interfere with gene
regulation mechanisms, against S. aureus suggest that the
synergistic eﬀect of LiF seems to be ampliﬁed in antibiotics
interfering with gene regulation mechanisms.
Wealsoexaminedtheassociationofeachceftazidimeand
sulfamethoxazole-trimethoprim with LiF against P. aerugi-
nosa and E. coli. A twofold reduction in the MIC of cef-
tazidime against P. aeruginosa was recorded while a fourfold
reduction was obtained against E. coli. Hence, we were4 International Journal of Microbiology
surprised to obtain a stronger reduction in the MIC of
ceftazidime against E. coli than P. aeruginosa as ceftazidime
is commonly used as an antipseudomonal agent [18]. The
stronger reduction in the MIC of ceftazidime associated with
LiF against E. coli suggests this organism is more strongly
aﬀected by an inhibition of enolase than P. aeruginosa,
as demonstrated by our results. This could be explained
by the fact that enolase is an abundant protein in E. coli
compared to P. aeruginosa, a nonfermenter, which lacks
glycolytic enzymes [19, 20]. Thus, E. coli would be more
sensitive to an inhibition of glycolytic enzymes than P.
aeruginosa. We also observed a twofold reduction in the
MIC of sulfamethoxazole-trimethoprim associated with LiF
against E. faecalis and P. aeruginosa and a fourfold reduction
against E. coli. E. coli showed a greater susceptibility to the
association of sulfamethoxazole-trimethoprim with LiF than
P. aeruginosa and E. faecalis, with this phenomenon being
reminiscent of the one observed for ceftazidime associated
with LiF against E. coli. These results imply that inhibition of
enolase increases the susceptibility of E. coli to antimicrobial
agents possessing distinct mode of actions. The resolution
of additional functions attributed to enolase would allow
a better understanding as to how ﬂuoride inhibition of
enolase renders E. coli more susceptible to the action of
antimicrobial agents. The reduction in the MICs of the
antibiotics associated with LiF against P. aeruginosa indicates
that LiF has targets other than enolase in this organism.
ThereductionoftheMICsofthestreptomycinassociated
with LiF was twofold when used against A. baumannii,
K. pneumoniae,a n dS. marcescens and eightfold against S.
pneumoniae (Table 2). We believe the greater reduction of
the MIC of streptomycin associated with LiF against S.
pneumoniae could be caused by ﬂuoride inhibiting multiple
targets in this organism. Indeed, it has been demonstrated
in S. pyogenes that ﬂuoride downregulates the expression
of the M-protein and glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) while suppressing the expression of the
translation factor Tu [21]. We speculate that ﬂuoride acts in
a similar manner in S. pneumoniae as both S. pneumoniae
and S. pyogenes belong to the same genus and, hence, are
closely related. The inhibition of enolase and GAPDH as
well as the suppression of Tu suggests that ﬂuoride interferes
with gene expression regulation mechanisms in this genus
rendering them more susceptible to antibiotic treatment.
In addition, the MIC of erythromycin associated with LiF
against S. pneumoniae was reduced sixteenfold. The stronger
reductions in MICs of streptomycin and erythromycin
associated with LiF against S. pneumoniae are indicative of
a greater susceptibility of this organism to this association.
Champney et al. [22] have demonstrated that ketolides
inhibit not only translation but also the assembly of the 50S
ribosomal subunit in S. pneumoniae. The inhibition of both
translation and the assembly of the 50S ribosomal subunit
in S. pneumoniae by ketolides could explain the greater
susceptibility to erythromycin of this organism compared
to the other bacteria tested in our study. The reductions in
the MICs of erythromycin associated with LiF were eightfold
against A. baumannii and twofold against K. pneumoniae
and S. marcescens (Table 2) implying that A. baumannii,l i k e
S. pneumoniae, is more susceptible to this association than
K. pneumoniae and S. marcescens. Collectively, these results
suggest streptomycin and erythromycin associated with
LiF interfere with gene regulation mechanisms in a more
pronounced manner in S. pneumoniae and A. baumannii.
The eﬀect of LiF on amoxicillin against A. baumannii, K.
pneumoniae,a n dS. marcescens was also veriﬁed. A greater-
than two-fold reduction in the MIC of amoxicillin associated
with LiF was observed against A. baumannii,f o l l o w e db ya
fourfold reduction against K. pneumoniae, S. marcescens,a n d
S. pneumoniae (Table 2). The greater reduction in the MIC
of amoxicillin associated with LiF against K. pneumoniae, S.
marcescens,a n dS. pneumoniae suggests that this association
is more eﬀective against these organisms than A. baumannii.
The fourfold reduction obtained for S. marcescens and K.
pneumoniae is reminiscent of the one observed against E.
coli following a challenge of ceftazidime and trimethoprim-
sulfamethoxazole each associated with LiF (Table 1). It is
interesting to note that both ceftazidime and amoxicillin
target cell wall synthesis and that when associated with
LiF provoke a fourfold reduction against the Enterobacteria.
These preliminary results suggest the association of LiF with
antibiotics inhibiting cell wall synthesis could be eﬀective
against Enterobacteria.
The last association we tested was that of LiF with
ciproﬂoxacin where we obtained a two-fold reduction in
the MIC of ciproﬂoxacin against A. baumannii and K.
pneumoniae and a fourfold reduction against S. marcescens
and S. pneumoniae (Table 2). It is unclear why we observed
a twofold reduction in the MIC of ciproﬂoxacin in com-
bination with LiF against K. pneumoniae and a fourfold
reduction against S. marcescens, as both of these organisms
demonstrated an identical reduction in the MIC of amoxi-
cillin associated with LiF. Further testing of the combination
of ciproﬂoxacin and LiF against other Enterobacteria would
be required to observe the eﬀects of this association on
these types of organisms. Moreover, ciproﬂoxacin is the only
antibiotic used in this study targeting DNA synthesis and
thus renders interpretation of the results diﬃcult.
This preliminary study sheds light on the potential
of LiF as an adjuvant in antibiotic therapy. Antibiotics
targeting DNA, membrane, and protein synthesis all showed
at least twofold reductions in their MICs against both
Gram-negative and Gram-positive bacteria. Our results
demonstrate that LiF could be used as a novel adjuvant
in combination therapy with antibiotics to treat infections,
particularly those caused by antibiotic-resistant microor-
ganisms which normally require high doses of antibiotics,
thus supporting the data obtained previously. Data from
our laboratory have demonstrated that LiF alone inhibits
bacterial growth by 30% in pseudomonal strains suggesting
it possesses bacteriostatic activity (unpublished). This same
study also revealed twofold reductions in the MICs of
ceftazidime in combination with LiF and was used against
pseudomonal strains, implying that LiF and ceftazidime
act in synergy. Taken together, these results indicate that
the association between ceftazidime and LiF represents a
form of combination therapy against pseudomonal strains
worth exploring. The study described here establishes aInternational Journal of Microbiology 5
pronounced synergistic eﬀect between LiF and erythromycin
compared to the other antibiotics tested against S. pneu-
moniae and A. baumannii. Although these in vitro results
are exciting, the eﬀects of using combination therapy of LiF
and antibiotics in vivo remain unknown. Furthermore, our
results need conﬁrmation by testing antibiotics other than
the ones used here against the bacteria used in our study.
For example, testing antibiotics targeting protein synthesis
other than doxycycline in combination with LiF against S.
aureus, E. faecalis, and E. coli would be required to conﬁrm
the idea that S. aureus is more susceptible to this type of
association than are E. faecalis and E. coli. Likewise, testing
theassociationofotherantibioticstargetingthecellwallwith
LiF as well as the association of antibiotics targeting DNA
synthesis in combination with LiF against Enterobacteria
will allow a better understanding of the consequences of
these associations on these bacteria. The association of
antibiotics targeting the 50S ribosomal subunit with LiF
against A. baumannii, S. pneumoniae, and other bacteria
needs to be veriﬁed in order to determine if the synergistic
eﬀect of erythromycin and LiF demonstrated in our study
is speciﬁc to this antibiotic. In spite of the limitations of
our study, we nonetheless believe that the results obtained
here hold the potential for the development of future
combination therapies used to eradicate infections caused
by drug-resistant bacteria. The development of combination
therapy represents an alternative to prescribing high doses
of antibiotics used to treat infections resulting from resistant
pathogens.
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